E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/29/2006 in the Prospect News Biotech Daily.

WayPoint: Promising results in study of Hangover-Free patch

By E. Janene Geiss

Philadelphia, June 29 - WayPoint Biomedical, Inc. said Thursday that it has received extremely promising results from a recently completed clinical study to ascertain the effectiveness of its over-the-counter, Health-Essist Hangover-Free Patch product for relieving the effects of alcohol consumption.

The study concluded that 83% of the subjects who tested WayPoint's Hangover-Free product reported an improvement in their condition the morning after consumption of alcohol, while only 12% of the subjects who wore the placebo reported minimal improvement in their condition the following day, according to a company news release.

The most frequent Hangover-Free Patch benefits reported by subjects were the "loss of headache" and "less dry mouth effect," suggesting that the dehydrating effects of alcohol were being mitigated by the transdermally delivered product, officials said.

Completed by U.K.-based Scientific Services Derby, the independent blind study was conducted over a six-week period using subjects who routinely consumed a significant quantity of alcohol.

The individuals were represented by at least three of the five acknowledged alcohol biotypes.

Prior to the testing, each subject completed Scientific Services Derby's proprietary alcohol biotype questionnaire.

They were given randomly labeled placebo and non-placebo patches to apply to their upper arm during routine weekend drinking.

The instructions were to apply the patch prior to drinking their usual alcoholic beverages of choice and record their findings as soon as possible the morning after.

"The results of this pilot study were encouraging considering the fact that the team administering this trial had anticipated a strong placebo effect from using the patches," study scientist Jim Campbell said in the release.

WayPoint, a wholly owned subsidiary of Huntington Beach, Calif.-based WayPoint Biomedical Holdings, Inc., is a biomedical technology company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.